• GT Biopharma held its annual stockholder meeting on Aug. 14, 2026.
• Stockholders selected four directors to serve on the board.
• Appointment of Weinberg & Company as independent accountant for the year ending Dec. 31, 2026 was ratified.
• Charter amendment authorizing a 1-for-10 to 1-for-30 reverse split, if implemented, was adopted; board will set ratio and timing.
• Two amendments to the 2022 Omnibus Incentive Plan were adopted, adding 3.5 million shares and an automatic annual increase feature.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038446), on August 14, 2026, and is solely responsible for the information contained therein.